These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29844047)

  • 1. Clofazimine for the Treatment of Mycobacterium kansasii.
    Srivastava S; Gumbo T
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844047
    [No Abstract]   [Full Text] [Related]  

  • 2. Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection.
    Srivastava S; Boorgula GD; Wang JY; Huang HL; Howe D; Gumbo T; Heysell SK
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0232021. PubMed ID: 35315686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.
    Srivastava S; Pasipanodya J; Sherman CM; Meek C; Leff R; Gumbo T
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2273-9. PubMed ID: 25645830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoniazid pharmacokinetics/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasii.
    Boorgula GD; Singh S; Shankar P; Gumbo T; Heysell SK; Srivastava S
    Tuberculosis (Edinb); 2023 Jan; 138():102289. PubMed ID: 36512853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii.
    Chapagain M; Gumbo T; Heysell SK; Srivastava S
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32690646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates.
    da Silva Telles MA; Chimara E; Ferrazoli L; Riley LW
    J Med Microbiol; 2005 Oct; 54(Pt 10):975-979. PubMed ID: 16157553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omadacycline Pharmacokinetics/Pharmacodynamics in the Hollow Fiber System Model and Potential Combination Regimen for Short Course Treatment of Mycobacterium kansasii Pulmonary Disease.
    Singh S; Gumbo T; Boorgula GD; Shankar P; Heysell SK; Srivastava S
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0068722. PubMed ID: 35976006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clofazimine as a substitute for rifampicin improves efficacy of
    Salillas S; Raaijmakers J; Aarnoutse RE; Svensson EM; Asouit K; van den Hombergh E; Te Brake L; Stemkens R; Wertheim HFL; Hoefsloot W; van Ingen J
    Antimicrob Agents Chemother; 2024 Mar; 68(3):e0115723. PubMed ID: 38259101
    [No Abstract]   [Full Text] [Related]  

  • 9. Nouveau short-course therapy and morphism mapping for clinical pulmonary
    Srivastava S; Wang JY; Magombedze G; Chapagain M; Huang HL; Deshpande D; Heysell SK; Pasipanodya JG; Gumbo T
    Antimicrob Agents Chemother; 2023 May; 95(5):. PubMed ID: 33558291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.
    Ferro BE; Srivastava S; Deshpande D; Pasipanodya JG; van Soolingen D; Mouton JW; van Ingen J; Gumbo T
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3779-85. PubMed ID: 27067317
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Luo J; Yu X; Jiang G; Fu Y; Huo F; Ma Y; Wang F; Shang Y; Liang Q; Xue Y; Huang H
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Disseminated disease by Mycobacterium kansasii resistant to isoniazid and rifampin in patients] with AIDS].
    Ibarrola M; Baraia-Etxaburu J; Sánchez R; Teira R; Unzaga J; Miguel Santamaría J
    Enferm Infecc Microbiol Clin; 2001 Feb; 19(2):80-2. PubMed ID: 11333577
    [No Abstract]   [Full Text] [Related]  

  • 13. Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex.
    Rastogi N; Goh KS; Bryskier A
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1433-8. PubMed ID: 8092850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance profile of Mycobacterium kansasii clinical isolates before and after 2-month empirical antimycobacterial treatment.
    Zhang Y; Yu C; Jiang Y; Zheng X; Wang L; Li J; Shen X; Xu B
    Clin Microbiol Infect; 2023 Mar; 29(3):353-359. PubMed ID: 36209990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease.
    Srivastava S; Pasipanodya JG; Heysell SK; Boorgula GD; Gumbo T; McShane PJ; Philley JV
    J Glob Antimicrob Resist; 2022 Mar; 28():71-77. PubMed ID: 34933140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of pulmonary disease caused by Mycobacterium kansasii.
    Huang HL; Lu PL; Lee CH; Chong IW
    J Formos Med Assoc; 2020 Jun; 119 Suppl 1():S51-S57. PubMed ID: 32505588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.
    Shitrit D; Baum GL; Priess R; Lavy A; Shitrit AB; Raz M; Shlomi D; Daniele B; Kramer MR
    Chest; 2006 Mar; 129(3):771-6. PubMed ID: 16537880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.
    Alcaide F; Calatayud L; Santín M; Martín R
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4562-5. PubMed ID: 15561826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug susceptibility profile of Mycobacterium kansasii clinical isolates from Brazil.
    de Carvalho LD; de Queiroz Mello FC; Redner P; Campos CED; de Souza Caldas PC; da Silva Lourenço MC; Ramos JP
    J Glob Antimicrob Resist; 2019 Dec; 19():228-230. PubMed ID: 31100506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethambutol-induced bullous skin lesions in
    Kollipara VK; Horowitz M; Lantz J; Nagy-Agren S
    Int J Mycobacteriol; 2022; 11(1):120-122. PubMed ID: 35295035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.